Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
- PMID: 23864097
- DOI: 10.1093/annonc/mdt253
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
Abstract
Background: There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.
Patients and methods: A cohort of 667 consecutive patients with mCRC from the general community treated from 2006 to 2011 with CAPEOX and bevacizumab as standard first-line therapy was compared with a cohort of 213 patients treated with CAPEOX from 2003 to 2006, before bevacizumab was approved. Main outcome measures were progression-free survival (PFS) and overall survival (OS). Differences in outcome were tested using Kaplan-Meier curves and log-rank tests, and multivariate analyses were carried out using Cox Proportional Hazards models.
Results: Patients treated with CAPEOX and bevacizumab with primary tumors originating in the sigmoid colon and rectum had a significantly better outcome than patients with primary tumors originating from the cecum to the descending colon, both for PFS (median PFS 9.3 versus 7.2 months; hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.56-0.82) and for OS (median OS 23.5 versus 13.0 months; HR 0.47, 95% CI 0.38-0.57). This difference was confirmed in multivariate analyses after adjustment for other potentially prognostic factors. For patients treated with CAPEOX, there was no association between primary tumor location and outcome, neither in unadjusted nor adjusted analyses.
Conclusions: The addition of bevacizumab to CAPEOX in first-line treatment of patients with mCRC may primarily benefit patients with primary tumors originating in the rectum and sigmoid colon. This hypothesis needs to be validated in data from completed randomized trials.
Clinicaltrialsgov identification number: NCT00212615.
Keywords: bevacizumab; biomarker; chemotherapy; metastatic colorectal cancer; primary tumor.
Comment in
-
Can tumor location predict effectiveness of bevacizumab conducted in the first-line setting for metastatic colorectal cancer.Ann Oncol. 2014 Feb;25(2):545-6. doi: 10.1093/annonc/mdt569. Epub 2014 Jan 12. Ann Oncol. 2014. PMID: 24419236 No abstract available.
Similar articles
-
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.Cancer Med. 2013 Apr;2(2):234-42. doi: 10.1002/cam4.71. Epub 2013 Mar 6. Cancer Med. 2013. PMID: 23634291 Free PMC article. Clinical Trial.
-
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791631 Free PMC article.
-
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.Ann Surg Oncol. 2014 May;21(5):1632-40. doi: 10.1245/s10434-013-3463-y. Epub 2014 Jan 14. Ann Surg Oncol. 2014. PMID: 24419756 Free PMC article.
-
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.Med Oncol. 2010 Sep;27(3):585-91. doi: 10.1007/s12032-009-9253-5. Epub 2009 Jun 13. Med Oncol. 2010. PMID: 19526201 Review.
-
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27. Clin Colorectal Cancer. 2014. PMID: 24768040 Review.
Cited by
-
Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7.Front Cardiovasc Med. 2023 Feb 3;10:1002438. doi: 10.3389/fcvm.2023.1002438. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36818331 Free PMC article. Review.
-
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study.Clin Cancer Res. 2022 Jul 1;28(13):2818-2829. doi: 10.1158/1078-0432.CCR-22-0112. Clin Cancer Res. 2022. PMID: 35472243 Free PMC article. Clinical Trial.
-
A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer.Front Oncol. 2022 Mar 17;12:808808. doi: 10.3389/fonc.2022.808808. eCollection 2022. Front Oncol. 2022. PMID: 35372058 Free PMC article.
-
Microbial Community Profiling Distinguishes Left-Sided and Right-Sided Colon Cancer.Front Cell Infect Microbiol. 2020 Nov 26;10:498502. doi: 10.3389/fcimb.2020.498502. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 33324571 Free PMC article.
-
Clinicopathological differences and correlations between right and left colon cancer.World J Clin Cases. 2020 Apr 26;8(8):1424-1443. doi: 10.12998/wjcc.v8.i8.1424. World J Clin Cases. 2020. PMID: 32368535 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical